Regeneron Pharmaceuticals Inc. (REGN)

296.52
1.59 0.53
NASDAQ : Health Technology
Prev Close 298.11
Open 298.20
Day Low/High 294.69 / 300.32
52 Wk Low/High 287.66 / 442.00
Volume 586.63K
Avg Volume 859.20K
Exchange NASDAQ
Shares Outstanding 107.73M
Market Cap 33.23B
EPS 22.60
P/E Ratio 14.35
Div & Yield N.A. (N.A)

Latest News

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These bearish bets are showing both technical and quantitative deterioration.

A Biotech Biggie, a Watchmaker and Other Stocks That Look Good Short

REGN, NOMD, LMNR, MOV and HTHT all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SCM, UFCS Downgrades: GCO, GIII, JE, KR, MLAB, OCC, PK, REGN, TAIT, WMK Initiations: HMI, PVTL, SMAR Read on to get TheStreet Quant Ratings' detailed report:

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

FDA Approves EYLEA® (aflibercept) Injection For Diabetic Retinopathy

FDA Approves EYLEA® (aflibercept) Injection For Diabetic Retinopathy

- EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?

Regeneron Declines on First-Quarter Earnings Miss

Regeneron Declines on First-Quarter Earnings Miss

The company misses big on analysts bottom-line expectations.

Regeneron Pharmaceuticals Expected to Earn $5.48 a Share

Regeneron Pharmaceuticals Expected to Earn $5.48 a Share

Regeneron Pharmaceuticals revenue expected to rise 16.8% to $1.8 billion.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Regeneron Announces Upcoming Investor Conference Presentations

Regeneron Announces Upcoming Investor Conference Presentations

TARRYTOWN, N.Y.

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Noteworthy Monday Option Activity: REGN, CARA, RGNX

Noteworthy Monday Option Activity: REGN, CARA, RGNX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Regeneron Pharmaceuticals, Inc. , where a total of 9,068 contracts have traded so far, representing approximately 906,800 underlying shares.

A Bullish Play on Netflix

A Bullish Play on Netflix

Netflix is bullish, but faces key resistance before it can make a big run higher.

TheStreet Quant Rating: C+ (Hold)